Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Return on Equity (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Return on Equity for 6 consecutive years, with 29.18% as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Return on Equity fell 2841.0% year-over-year to 29.18%, compared with a TTM value of 29.18% through Sep 2019, down 2841.0%, and an annual FY2018 reading of 1.51%, down 99.0% over the prior year.
  • Return on Equity was 29.18% for Q3 2019 at Larimar Therapeutics, up from 42.72% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.26% in Q2 2015 and bottomed at 42.72% in Q2 2019.
  • Average Return on Equity over 5 years is 5.74%, with a median of 0.52% recorded in 2016.
  • The sharpest move saw Return on Equity rose 3bps in 2017, then plummeted -4174bps in 2019.
  • Year by year, Return on Equity stood at 0.41% in 2015, then decreased by -11bps to 0.46% in 2016, then plummeted by -36bps to 0.62% in 2017, then plummeted by -84bps to 1.14% in 2018, then tumbled by -2450bps to 29.18% in 2019.
  • Business Quant data shows Return on Equity for LRMR at 29.18% in Q3 2019, 42.72% in Q2 2019, and 28.21% in Q1 2019.